Abstract
Drug-induced liver injury, and more specifically drug-induced cholestasis, is responsible for a large amount of hospitalizations and attrition of new drug candidates in preclinical drug development. Drug-induced cholestasis can be triggered by drugs that are inhibitors of the hepatic bile acid transporters. Therefore, it is of considerable interest in preclinical drug development to detect whether new candidate drugs can cause interference with the hepatic bile acid transporters. Although several cost-effective and fast in vitro assays are available to that end, these do not mimic the in vivo situation completely. In vivo research to monitor a new candidate drug’s cholestatic potential is still relevant, yet is time-consuming and requires invasive sampling of a lot of laboratory animals. In this chapter, a protocol is provided to determine in vivo inhibition of the hepatic bile acid transporters in mice, using the nuclear imaging techniques positron emission tomography and single photon emission computed tomography. The protocol includes detailed information on preparation of the animal, scan acquisition, processing, and (statistical) analysis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bleibel W, Kim S, D’Silva K et al (2007) Drug-induced liver injury: review article. Dig Dis Sci 52:2463–2471
Regev A (2014) Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis 34:227–239
Yang K, Ock KK, Sedykh A et al (2013) An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J Pharm Sci 102:3037–3057
Klaassen CD, Aleksunes LM (2014) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1–96
Alrefai W, Gill RK (2007) Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 24:1803–1823
Bohan A, Boyer JL (2002) Mechanisms of hepatic transport of drugs: Implications for cholestatic drug reactions. Semin Liver Dis 22:123–136
de Lima Toccafondo Vieira M, Tagliati CA (2014) Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools. Expert Opin Drug Metab Toxicol 10:581–597
Bergman E, Hedeman M, Bondesson U et al (2010) The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo. Xenobiotica 40:558–568
Sjögren E, Hedeland M, Bondesson U et al (2014) Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. Eur J Pharm Sci 57:214–223
Shin DH, Park SH, Jeong SW et al (2014) Hepatic uptake of epirubicin by isolated rat hepatocytes and its biliary excretion after intravenous infusion in rats. Arch Pharm Res 37:1599–1606
Cunha L, Horvath I, Ferreira S et al (2014) Preclinical imaging: an essential ally in modern biosciences. Mol Diagnosis Ther 18:153–173
Neyt S, Huisman MT, Vanhove C et al (2013) In vivo visualization and quantification of (disturbed) Oatp-mediated hepatic uptake and Mrp2-mediated biliary excretion of 99mTc-mebrofenin in mice. J Nucl Med 54:624–630
Neyt S, Vliegen M, Verreet B et al (2016) Synthesis, in vitro and in vivo small-animal SPECT evaluation of novel technetium labeled bile acid analogues to study (altered) hepatic transporter function. Nucl Med Biol 43:642–649
Shingaki T, Takashima T, Ijuin R et al (2013) Evaluation of Oatp and Mrp2 activities in hepatobiliary excretion using newly developed positron emission tomography tracer [11C]dehydropravastatin in rats. J Pharmacol Exp Ther 347:193–202
Chen X, Zhang C, Wang H et al (2009) Altered integrity and decreased expression of hepatocyte tight junctions in rifampicin-induced cholestasis in mice. Toxicol Appl Pharmacol 240:26–36
Vavricka SR, Van Montfoort J, Ha HR et al (2002) Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 36:164–172
De Lombaerde S, Neyt S, Kersemans K et al (2017) Synthesis, in vitro and in vivo evaluation of 3β-[18F]fluorocholic acid for the detection of drug-induced cholestasis in mice. PLoS One 12(3):e0173529
Hartman JC, Brouwer K, Mandagere A et al (2010) Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 88:682–691
Fattinger K, Funk C, Pantze M et al (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–231
Leslie EM, Watkins PB, Kim RB et al (2007) Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: a mechanism for species differences in hepatotoxicity. J Pharmacol Exp Ther 321:1170–1178
Ghibellini G, Johnson BM, Kowalsky RJ et al (2004) A novel method for the determination of biliary clearance in humans. AAPS J 6:45–56
Ghibellini G, Leslie EM, Pollack GM et al (2008) Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharm Res 25:1851–1860
Diehl KH, Hull R, Morton D et al (2001) A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 21:15–23
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
De Lombaerde, S., Neyt, S., Vanhove, C., De Vos, F. (2019). In Vivo Measurement of Hepatic Drug Transporter Inhibition with Radiolabeled Bile Acids. In: Vinken, M. (eds) Experimental Cholestasis Research. Methods in Molecular Biology, vol 1981. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9420-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9420-5_6
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9419-9
Online ISBN: 978-1-4939-9420-5
eBook Packages: Springer Protocols